Moderna announced it would request authorization from the Food and Drug Administration to administer a smaller dose of its COVID-19 vaccine to children ages 6 months old to 6 years old.

Clinical trial data showed that children under 6 mounted a robust neutralizing antibody response comparable to young adults when given a dose a quarter as strong, the company said on Wednesday.